Response to Comment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women"

Plain-language summary

Published 2021 in Science, this work by Klein S and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

• Authors' published Response to Comment defending the Yoshino 2021 NMN muscle-insulin-sensitivity trial in Science (2021)
• A correspondence/letter, not an original study; presents no new trial data
• Useful for understanding the scientific debate around the original prediabetic-women NMN trial

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to benefits decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.